Every guide.

HGH fragment 177-191. Phase IIb obesity trial NEGATIVE — honest framing, FDA GRAS for food not drug approval.

Pro-apoptotic peptide targeting adipose vasculature. Phase I kidney toxicity halted development — honest safety framing.

Long-acting amylin analog. 9.7% body-weight reduction in Phase 2 monotherapy; 20.4% for CagriSema in REDEFINE-1.

An engineered oxyntomodulin analog approved in China — the most biomimetic design in the class, and the lowest dual-agonist result.

Complete research guide — triple GIP/GLP-1/glucagon agonist: the Phase II readout that reset the upper bound of pharmacological body-weight reduction.

The dual agonist that picked glucagon instead of GIP — ~19% in Phase 2, and a liver programme that may matter more than the obesity one.

Complete research guide — FDA-approved dual GIP/GLP-1 agonist: SURMOUNT, SURPASS, and the field-defining body-weight endpoint curves.

Six compounds ranked two ways — by trial magnitude and by evidence quality — and why those two orderings disagree.

Cagrilintide + semaglutide fixed-dose combination. 20.4% mean body-weight reduction at 68 weeks — the largest pharmacological figure documented.

Semaglutide, tirzepatide, retatrutide, mazdutide, cagrisema. The current state of the class, by trial readout.

How the GLP-1 receptor agonists got from exendin-4 to triple agonists — and where the class is going next.

A Phase 3 trial site or the research-chemical market. There is no prescription route, no compounding route, and no telehealth route.

No — not anywhere. Where the TRIUMPH Phase 3 programme stands, what it has to establish, and why an unapproved compound is sold openly.

24.2% body-weight reduction at 48 weeks (NEJM 2023). The setup for the Phase III readouts in progress.

The honest version is a distribution, not a photograph: −24.2% mean at 12 mg, 83% losing 15%+, and the one in six who did not.

The published Phase 2 protocol — 1/4/8/12 mg targets, 2–4 mg starting doses, 12-week escalation — and why there is no approved dose.

Class-typical gut effects plus the dose-dependent heart-rate rise peaking at week 24 — and what 338 people over 48 weeks cannot detect.

GIP + GLP-1 + glucagon receptor engagement. Why adding the glucagon arm changes the energy-balance math.

Two pharmaceutical heavyweights compared. Where the dose-response curves diverge.

NEJM 2022 Phase III in obesity — 22.5% mean body weight reduction at 72 weeks, the highest pharmaceutical figure on record.

STEP-1's four-step, 16-week climb from 0.25 mg to 2.4 mg — and the cardiovascular outcome data no other compound in the class has.

The SURMOUNT-1 escalation — 2.5 mg start, 2.5 mg steps every four weeks — and the estimand difference behind 20.9% versus 22.5%.

How a single 39-residue peptide engages two incretin receptors — and why the GIP arm changes the outcome.

Indication, dosing schedule, GI tolerability, and where the compounded vs. branded distinction matters.

SURMOUNT-5 head-to-head — tirzepatide outperformed semaglutide on body-weight reduction with comparable adverse-event profile.

No retail price exists for an unapproved drug. How to normalise research-vial pricing to cost per mg, and why the cheapest sticker rarely is.

NNMT inhibitor (technically not a peptide). Oral research advantage, honest mouse-only evidence framing.

A 2026 sourcing guide for AOD-9604 (hGH fragment 176-191)

A 2026 sourcing guide for Adipotide (FTPP)

A 2026 sourcing guide for semaglutide as a research reference compound

Rarely wanted alone, usually sold beside semaglutide — and that pairing is where verification falls down.

2026 sourcing guide for the triple-agonist landmark — pre-approval framing, the FG-series codename problem, pricing, and the CoA red flags.

Sourcing tirzepatide for research — the 3 channels (prescription / 503A / RUO), pricing across them, and the identity-verification questions.

Complete research guide — identity, multifactorial mechanism, the 35:1 preclinical-to-human ratio, FDA Cat 2 / WADA S0 status.

Complete research guide — thymosin-β4 (1-43 fragment), actin binding, cell migration, and the cardiac-repair preclinical signal.

VEGF-driven angiogenesis (BPC-157) + actin-monomer-driven cell migration (TB-500). Where the mechanisms converge.

How a 15-residue peptide upregulates VEGFR2 expression and triggers tube formation in endothelial cell assays.

Where the gut-healing claim actually comes from — VEGF, NO synthase, and dose-response in rodent colitis models.

No study has ever measured a BPC-157 before and after. The whole human record is three uncontrolled pilot reports…

36 studies, 35 of them in animals, roughly 80% from one research group. What's claimed, what's behind each claim, and why the mechanism makes the breadth plausible.

No human dose-finding trial has ever been run. Why the animal doses do not convert, and why every online chart agrees with every other.

Reconstitution, half-life, route of administration, and what the literature does and doesn’t say about safety.

Retrospective chart review of 16 patients with intra-articular BPC-157 — phone-recall outcomes only, no controls.

No controlled human safety data exists — three small uncontrolled reports is the entire record. What the animal work shows and what the FDA concluded.

Two different molecules for two different problems. When the literature supports stacking, and when it doesn’t.

First systematic review of 36 studies on BPC-157 for orthopaedic indications. Honest about the human-evidence gap.

The peptides most-studied for joint health, ranked by published evidence — and the standard-of-care context they're usually compared against.

An honest review of the strongest recovery peptides, anchored to peer-reviewed evidence rather than marketing.

BPC-157 survives human gastric juice for over 24 hours, so rats were dosed in drinking water. What those studies…

The G-actin sequestration model — how Tβ4 controls the actin monomer pool and modulates cell motility.

Murine MI models show Tβ4-driven epicardial reactivation. Human Phase II hit the primary endpoint; Phase III is pending.

The most-stacked combination in research peptides. What the additive-mechanism case looks like and where it falls apart.

BPC-157 + TB-500 — the most-named peptide stack in the research community. Where the name came from, the mechanism, and what the evidence supports.

BPC-157, TB-500, and the BPC/TB blend. The class-level evidence picture and how the molecules differ.

Research sourcing guide — CAS 137525-51-0, the 503A Category 2 framing, real pricing benchmarks, and the BPC-specific red flags.

A 2026 sourcing guide for the pre-mixed BPC-157 + TB-500 blend

TB-500 buyer guide — the Tβ4 vs fragment distinction, mass-spec identity, and WADA S2 framing for research handlers.

Complete research guide — two molecules share the name: DAC vs. no-DAC half-life, the receptor pharmacology, and the missing human trials.

Synthetic GnRH decapeptide. Factrel discontinued; pulsatile-vs-continuous pharmacology, TRT-adjunct off-label.

GHRP family — high GH-release potency, tachyphylaxis limitation, cardiac-protection preclinical signal.

Long R3 IGF-1 with N-terminal extension. Extended half-life, reduced IGFBP binding — honest cancer-biology framing.

Complete research guide — the selective ghrelin-receptor agonist: the GH peptide that doesn’t spike cortisol or prolactin.

GHRH 1-29 analog — the 29-aa original used as Geref through 2008. Mechanism, evidence, and modern half-life context.

Complete research guide — FDA-approved stabilized GHRH analog, the gold standard for the class.

The growth-hormone axis ranked by evidence rather than reputation — and the hypertrophy outcome studies that mostly do not exist.

The published evidence on the CJC + ipamorelin combination — what’s actually been tested vs. claimed.

How a GHRH analog with a maleimidopropionyl modification ends up albumin-bound with an 8-day half-life.

No trial has ever dosed CJC-1295 and ipamorelin together. What each was given at separately, and why the DAC…

Two small 2006 trials are the entire human safety record for CJC-1295. They report no serious reactions over 28 to…

Different receptors, different pulse patterns. Why the "stack" became the dominant grey-market combination.

Both are stabilized GHRH analogs. Why one is FDA-approved and the other isn’t.

Tesamorelin (FDA-approved), CJC-1295, ipamorelin, sermorelin, hexarelin. The full landscape, in tiers.

CJC-1295 + Ipamorelin + Tesamorelin — supra-additive GH release across GHRH + GHRP receptors. Why athletes stack all three.

Growth hormone secretagogue receptor pharmacology — why ipamorelin is more selective than GHRP-2 or hexarelin.

Ipamorelin has been given to humans in one published trial, at 0.03 mg/kg into a vein. What that trial found, and…

The honest before-and-after is a blood test, not a photo: IGF-1 restored to the young-adult range in 14 days in 1990s trials — and zero modern RCTs behind the transformation claims.

Tesamorelin cut visceral fat 15.2% in 26 weeks against a 5.0% gain on placebo. The measured before and after, the…

Pilot-stage trials in MCI and mild Alzheimer’s — directional cognitive signal, no Phase III evidence yet.

The rare compound here with a labelled dose rather than a reconstruction — and two correct numbers that cause most of the confusion.

The pivotal RCTs that earned FDA approval — VAT reduction, IGF-1 dynamics, and the long-term safety extension data.

The only compound in this class where side effects were measured rather than guessed. The glucose effect is the one with clinical weight.

DPP-4 resistance and the structural changes that turn a 30-minute peptide into a once-daily injectable.

The stabilized FDA-approved GHRH analog vs the discontinued original fragment — mechanism, half-life, evidence depth, regulatory status, and cost, compared honestly.

DAC vs no-DAC distinction is critical — mass-spec ID, half-life difference, pricing tiers, and storage stability.

A 2026 sourcing guide for the CJC-1295 / Ipamorelin 5mg/5mg blend

An 83-residue analog where folding matters as much as purity, and 'LR3' is the part that gets substituted.

A decapeptide whose effect inverts with delivery pattern — which makes the GnRH-analog family the substitution risk.

Six residues, cheap to make, rarely worth faking — so the sourcing question here is mostly about handling.

Ipamorelin sourcing — the Aib residue identity check, selectivity-vs-cost logic, and the CJC-1295 stack context.

Discontinued commercially, not for safety — which leaves two routes. Why degradation matters more than identity for this one.

Three channels: Egrifta prescription, 503A compounded, third-party tested RUO. Mass-spec on the trans-3-hexenoyl modified peptide.

Complete research guide — selective NNMT inhibitor: the murine adipose-tissue signal, the mechanism, and the absent human trials.

AED tripeptide for cartilage research. Khavinson cytogen — preclinical-strong, RCT-poor.

Complete research guide — Russian tetrapeptide aging program: Khavinson’s 1971 work, the telomerase claims, and the methodological gaps Western labs flagged.

Complete research guide — 16-residue mitochondrial-encoded peptide: the "exercise mimetic" claim, the AMPK story, and the human-trial gap.

Complete research guide — IV infusion, NMN, NR, NAM: the four ways to address declining cellular NAD+ and what the data actually supports.

EDR tripeptide, Khavinson school. Russian preclinical work, mitochondrial proposals, thin Western RCT base.

Complete research guide — mitochondria-targeted tetrapeptide, FDA-approved for Barth syndrome (Forzinity, Sept 2025).

KED tripeptide, Khavinson cytogen for vascular research. Thin Western RCT data.

Nicotinamide N-methyltransferase inhibition shifts the methyl-donor balance. The energy-expenditure case.

High-fat-fed mouse models show body-weight reduction without locomotor change. Sample size, dose, and translation limits.

An honest review of the most-cited anti-aging peptides, anchored to peer-reviewed evidence rather than longevity marketing.

Multi-decade Russian elderly-cohort trials. Survival, T-cell parameters, and the methodological limits of the data.

The pineal-telomerase upregulation hypothesis. What’s replicated, what isn’t, and what stays unfalsifiable.

How a 16-residue ORF-encoded peptide activates AMPK and modulates the AICAR pathway in muscle.

Murine models show insulin sensitization without exercise. The human-extrapolation problem.

MOTS-c activates AMPK and rises with exercise, which is where the exercise-mimetic framing comes from. What the…

No human trial has established a MOTS-c dose. The exact doses the mouse studies used, why mg/kg does not convert…

No published trial has ever given MOTS-c to a person, so no side effect has been measured. Any list with…

SS-31, MOTS-c, humanin, and the ORF-encoded peptide class. The state of the field as of 2026.

SIRT1-7 deacetylase dependence on NAD+. The mechanism that anchors most of the popular longevity-market claims for the molecule.

IV NAD+, NMN, NR, NAM. Bioavailability, tissue distribution, and where the head-to-head trials land.

Accelerated approval based on the pivotal TAZPOWER + extension data. The first disease-specific therapy for Barth.

Selective binding to cardiolipin in the inner mitochondrial membrane — how it preserves cristae structure and ETC efficiency.

Two mitochondrial peptides with different mechanisms. Where the use-cases overlap and where they diverge.

SS-31 + MOTS-c + NAD+ — three complementary mitochondrial mechanisms. Zero published controlled human trials of the combination.

AEDG tetrapeptide. Khavinson trials caveats, telomerase activation proposal, identity verification.

Mitochondrial-derived 16-aa peptide. 12S rRNA identity check, the exercise-mimetic marketing-vs-evidence gap.

NAD+ vs NMN vs NR — identity verification, IV vs oral, and the cofactor-grade purity threshold for research.

Elamipretide — FDA-approved Forzinity (Sept 2025) for Barth syndrome. 3 channels: prescription, 503A, RUO.

Master cellular antioxidant tripeptide. IV vs oral vs liposomal, the FDA Philippines IV skin-whitening warning.

Acetyl Hexapeptide-3 — the "Botox-like" SNAP-25 inhibitor. Topical anti-wrinkle evidence and cosmeceutical regulatory framing.

Complete research guide — endogenous copper tripeptide that declines with age, with the strongest topical signal in the catalog.

BPC-157 + TB-500 + GHK-Cu in one 70 mg vial. Per-constituent mechanism and evidence — and the honest gap: zero trials on the combined stack.

Complete research guide — the master endogenous antioxidant: redox cycling, IV vs. oral controversy, and the skin-lightening evidence base.

Palmitoyl Pentapeptide-4 (KTTKS). Topical collagen-stimulating cosmeceutical with dermatology RCT base.

The peptides most-studied for hair growth, ranked by published evidence — and honestly compared to minoxidil and finasteride.

An honest review of the strongest skin-health peptides, anchored to where the published evidence actually supports each route of administration.

Carrier choice matters. How tallow, ceramide, and aqueous bases change the GHK-Cu delivery profile.

Type I/III procollagen mRNA upregulation in dermal fibroblasts. The biochemical case in dermal-aging (photoaging) research.

Anagen-phase prolongation in hair-pluck cultures. The case for and against scalp injections vs. topicals.

Topical GHK-Cu has 12-week controlled cosmetic data in 71 women. Injectable GHK-Cu has no human trial at all. The…

RCTs on GHK-Cu topical creams in photoaged skin — wrinkle depth, hydration, elasticity. Effect sizes and study limits.

Two routes, two evidence bases. Topical has studied concentrations; injectable has zero human RCTs and a copper-load question nobody has looked at.

Diabetic ulcer and burn-wound trials. Where the topical formulation reaches and where systemic injection adds nothing.

The route-of-administration debate. Why topical formulations dominate the published literature.

GSH/GSSG ratio, glutathione peroxidase, and why "supplementing antioxidants" isn’t the same as raising cellular GSH.

A class of trials with positive descriptive findings but persistent methodological holes — and an FDA warning letter on IV use.

The class-level landscape. Where the topical evidence is real (GHK-Cu) and where it isn’t (most else).

A 2026 sourcing guide for Argireline (acetyl hexapeptide-8)

GHK-Cu sourcing — copper-complexed vs uncomplexed identity, blue-powder check, topical vs injectable evidence, and pricing.

A 2026 sourcing guide for the GLOW Blend

Complete research guide — the DSIP nonapeptide: 1977 isolation, the sleep-architecture literature, and the trial-quality gap.

Complete research guide — FDA-approved melanocortin agonist for HSDD: Vyleesi, the Phase III data, and the off-label dose-response.

Complete research guide — Russian heptapeptide derived from tuftsin: GABAergic modulation, anti-anxiety claims, and the trial-quality picture.

Complete research guide — Russian heptapeptide derived from ACTH(4-10): BDNF upregulation and the stroke-recovery indication.

The peptides most-studied for cognition, ranked by published evidence — including Cerebrolysin's negative 2023 Cochrane finding.

The peptides most-studied for sexual health, ranked by published evidence — and honest about PT-141's 40% nausea rate and Melanotan II's melanoma concerns.

An honest review of the most-marketed sleep peptides, with explicit framing on where the published evidence supports the claims and where it doesn’t.

The slow-wave-sleep induction hypothesis — what the EEG data actually shows and where it doesn’t replicate.

Cortisol-suppression trials in chronic stress cohorts. Endpoint definitions, sample sizes, and study limits.

A history of Russian neuropeptide research — tuftsin, ACTH(4-10), and the molecules that didn’t cross the Western methodological bar.

The pivotal Phase III RECONNECT and PRISM studies — efficacy magnitude, adverse-event profile, and the FDA approval.

MC4R activation in the hypothalamus — the neural mechanism behind the sexual-arousal effect.

PT-141 is the rare peptide with an approved human dose: 1.75 mg by autoinjector. The label's numbers, its limits…

Bremelanotide was developed as a nasal spray first. Blood-pressure rises and erratic uptake killed that route, and…

Russian heptapeptide pair — two neuropeptide classes. Institute of Molecular Genetics provenance, honest Western RCT framing.

Russian GAD trials — symptom-scale response in 60–80% of cohorts, but limited blinding and small sample sizes.

Intranasal is Selank's registered clinical route in Russia, unlike most peptides sold as sprays. What the Russian…

How a stabilized tuftsin analog modulates GABA-A receptor expression and reduces anxiety-related behavior in models.

Both Russian-school neuropeptides. Different parent peptides, different receptor targets, different use-cases.

The ACTH(4-10)Pro-Gly-Pro structure and how it engages BDNF signaling without the corticotropic side-effects of full ACTH.

Russian post-stroke trials show motor-function improvement. Methodological details and the Western-replication gap.

DSIP, semax, selank, ipamorelin. Where the sleep-architecture claims have data and where they don’t.

Delta sleep-inducing nonapeptide — the receptor unidentified after 50 years. Sleep claim vs RCT gap.

Bremelanotide sourcing — Vyleesi prescription vs the third-party tested alternative, MC4R mechanism, and the melanotan II substitution risk.

Russian-approved heptapeptide. Tuftsin analog identity, nasal-spray vs injection forms.

Russian ACTH(4-7) analog for ischemic stroke. Heptapeptide identity check, nasal vs injection, the BDNF claim.

Complete research guide — the C-terminal tripeptide of α-MSH: melanocortin signaling, the cleanest preclinical signal for ulcerative colitis.

KEDG tetrapeptide, Khavinson school. Proposed thymic function support; single-source-dominance flagged.

28-aa Zadaxin/Thymalfasin. 35+ country approval, FDA-unapproved in US. 2025 BMJ TESTS Phase III sepsis negative.

KE dipeptide, Khavinson cytogen for immune cell proliferation. Honest evidence-base framing.

An honest review of the most-cited gut-health peptides, anchored to peer-reviewed preclinical evidence for GI indications.

The peptides most-studied for immune support, ranked by published evidence — including the negative 2025 TESTS Phase III sepsis trial on Thymosin Alpha 1.

DSS-induced colitis models, oral and topical formulations, and the dose-response. Human trials still pending.

MC1R-independent anti-inflammatory action. Why a 3-residue peptide retains the parent molecule’s function.

An elegant mechanism and the largest gap between marketing and published human evidence of anything in this library.

α-MSH C-terminal tripeptide. Anti-inflammatory without pigmentation, oral vs injectable forms for IBD research.

Approved in 30+ countries but not the US. Why the N-terminal acetyl group is the substitution point to check.

Complete legal framework — RUO under 21 CFR §809.10, 503A categories, WADA prohibition, customs, and the seller-vs-buyer asymmetry.

Why 0.9% benzyl alcohol is the standard diluent for peptide vials — and what the sterile-water and saline alternatives actually do.

The peptides with the lowest entry barriers for new researchers — ranked by safety, ease of use, and evidence depth.

An 8-criterion evaluation framework — purity, COA transparency, lab partners, returns — applied honestly across the major US vendors.

USA-specific buyer's guide — state legality, customs framework, FDA RUO labeling, payment processors, and shipping logistics.

Two documents, two purposes. The Certificate of Analysis grades the product; the Safety Data Sheet covers handling.

Most raw material is synthesised in China, including what Western brands relabel. What buying direct actually changes — and what it doesn't.

GLOW is BPC-157, TB-500 and GHK-Cu in one vial. Each has its own literature. The combination has none, and that…

No study has given BPC-157, TB-500 and GHK-Cu together. What each was administered at separately, and why a fixed…

Subcutaneous, IM and IV compared — why the gut destroys peptides, and why insulin-syringe units measure volume rather than dose.

Solid-phase peptide synthesis — the Merrifield method, coupling chemistry, and why HPLC purity matters for the final product.

Receptor binding, signal cascades, and the difference between peptide hormones and structural peptides.

A 2026 buyer's guide — the eight criteria, real price-per-mg ranges by class, the regulatory framing, and a 30-minute vendor verification checklist.

Identity, purity, endotoxin, microbial, heavy metals. The six tests on every COA — and what the numbers actually mean.

Why diluent goes down the vial wall, why swirling beats shaking, and how long a peptide lasts once it is in solution.

The international standard for testing-lab competence. Why accredited labs carry it, and what it changes about COA credibility.

NAD+ is a dinucleotide, not a peptide — it has no amino acids and no peptide bonds. Why it is sold beside…

A walk through the most-cited stacks (BPC+TB, CJC+ipamorelin) — what’s been tested, what’s extrapolated, and what’s pure marketing.

Vial size, diluent, dose — concentration, draw volume and U-100 syringe units, with every step of the arithmetic shown.

Why some peptides last 30 minutes and others last 8 days. DPP-4 cleavage, albumin binding, and structural modifications.

Cost-per-mg by class, the 4 levers that drive price, cycle-cost examples, and why cheap peptides should prompt questions.

How reverse-phase HPLC measures peptide purity, why 95% vs. 99% matters, and what the 220 nm chromatogram is actually showing you.

Frozen vs. refrigerated vs. room-temperature stability windows. Lyophilized vial life, post-reconstitution life, and freeze-thaw cycle limits.

The arbitrary 50-residue threshold, the practical differences, and why the cutoff actually matters in formulation.

What 'peptides for sale' actually means, why the prices scatter so wildly, and the one request that separates a seller who tests from one who doesn't.

There is no retail counter for research peptides, and the reason is structural. What genuinely is available locally, and what isn't.

What changed when the FDA shifted several peptides out of 503A compounding eligibility — and what it meant for the grey market.

Not a ranking — the one email that sorts the market, and the six supplier checks in order of how much signal each carries.

What "third-party verified" means in 2026: HPLC purity floor, per-lot third-party COA, mass-spec identity, and the documentation chain that defines the category.

Which peptides sit on the WADA prohibited list, which categories they fall under, and the in-competition vs. out-of-competition distinction.

The FDA regulatory category, what RUO products can and can’t be sold for, and how the line is enforced.

The 50-amino-acid line that separates a peptide from a protein. Why the distinction matters for half-life, synthesis, and oral bioavailability.

0.9% benzyl alcohol bacteriostatic water for peptide reconstitution — USP grade, 28-day in-use stability.

Prescription, 503A compounding or the research-chemical market — the compound decides which route is open to you, not the seller.